Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
Clinical trial NCT03630159 · COMPLETED
Trial details
- NCT number
- NCT03630159
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-09
- Primary completion
- 2021-07-20
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.